TITLE:
Gene-Eden-VIR Decreased Physical and Mental Fatigue in a Post Marketing Clinical Study That Followed FDA Guidelines; Results Support Microcompetition Theory
AUTHORS:
Hanan Polansky, Edan Itzkovitz
KEYWORDS:
Gene-Eden-VIR; Microcompetition; Fatigue; Mental Fatigue; Physical Fatigue; Latent; Virus; Human Papillomavirus; HPV; Epstein Barr Virus; EBV; Herpes Simplex Virus; HSV; Cytomegalovirus; CMV; Hepatitis C Virus; HCV
JOURNAL NAME:
Pharmacology & Pharmacy,
Vol.5 No.3,
March
27,
2014
ABSTRACT:
Objective: The Microcompetition with Foreign
DNA theory, proposed by Hanan Polansky in 2003, describes how latent viruses
can cause chronic conditions, including fatigue. The Gene-Eden-VIR formula was
designed to target latent viruses. Therefore, the theory predicts that
treatment with Gene-Eden-VIR will decrease fatigue in individuals infected with
a latent virus. The objective of this study was to test this prediction.
Framework: A post marketing clinical study that followed FDA guidelines.
Treatment: Gene-Eden-VIR, a dietary supplement. A capsule of Gene-Eden-VIR includes 100 mg of quercetin,
150 mg of green tea extract, 50 mg of cinnamon extract, 25 mg of licorice extract, and 100 mcg of
selenium. The treatment included 1, 2, 3, or 4 capsules per day, and lasted 2
to 54 weeks. Population: 100 individuals infected with a latent virus,
including the Human Papillomavirus (HPV), Epstein Barr Virus (EBV), Herpes
Simplex Virus (HSV), Human Cytomegalovirus (HCMV), and Hepatitis C Virus (HCV). Ages
ranged from 20 to 66. All participants reported a feeling of fatigue at the
start of the study. Specifically, 98, 90, and 79 participants reported a feeling of general, physical,
and mental fatigue, respectively. Results: Following treatment with Gene-Eden-VIR, 73.47%, 62.22%,
and 47.36% reported a decrease in their feeling of general, physical, and
mental fatigue, respectively. The participants also reported a statistically
significant decrease in every aspect of fatigue tested in the study. The
results also showed a duration effect, that is, those treated for 2 months or
more reported a larger decrease in their feeling of fatigue (general, p = 0.03, n = 65; physical and mental, p = 0.05, n = 70). The results showed no
interviewer bias, and no selection bias. In addition, the results showed
therapeutic consistency under varying manufacturing conditions. The
participants reported no side effects after taking Gene-Eden-VIR. Conclusions: This post marketing
clinical study showed that treatment with Gene-Eden-VIR safely decreased the feeling of general,
physical, and mental fatigue in individuals infected with a latent virus. Since most individuals
are infected with a latent virus, health care practitioners should recommend Gene-Eden-VIR as a
first line treatment for fatigue. The results of this post marketing clinical
study support the Microcompetition with Foreign DNA theory.